Vera Therapeutics, Inc. (VERA) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -415.76M USD | Operating Income (Loss) |
| Revenue | (m) | |
| Cost of products and services | (m) | |
| Research and development | 261.87M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-415.76M | (m) | (m) | $261.87M | (m) | (m) |
| 2026-03-31 | $-383.41M | (m) | (m) | $259.99M | (m) | (m) |
| 2025-12-31 | $-315.47M | (m) | (m) | $215.26M | (m) | (m) |
| 2025-09-30 | $-270.18M | (m) | (m) | $189.29M | (m) | (m) |
| 2025-06-30 | $-236.05M | (m) | (m) | $173.13M | (m) | (m) |
| 2025-03-31 | $-193.25M | (m) | (m) | $144.25M | (m) | (m) |
| 2024-12-31 | $-167.17M | (m) | (m) | $126.17M | (m) | (m) |
| 2024-09-30 | $-145.28M | (m) | (m) | $113.61M | (m) | (m) |
| 2024-06-30 | $-117.24M | (m) | (m) | $89.40M | (m) | (m) |
| 2024-03-31 | $-101.87M | (m) | (m) | $76.32M | (m) | (m) |
| 2023-12-31 | $-102.01M | (m) | (m) | $78.22M | (m) | (m) |
| 2023-09-30 | $-108.56M | (m) | (m) | $84.12M | (m) | (m) |
| 2023-06-30 | $-112.05M | (m) | (m) | $87.67M | (m) | (m) |
| 2023-03-31 | $-105.14M | (m) | (m) | $81.55M | (m) | (m) |
| 2022-12-31 | $-90.90M | (m) | (m) | $68.99M | (m) | (m) |
| 2022-09-30 | $-73.91M | (m) | (m) | $55.07M | (m) | (m) |
| 2022-06-30 | $-55.91M | (m) | (m) | $38.98M | (m) | (m) |
| 2022-03-31 | $-46.71M | (m) | (m) | $32.10M | (m) | (m) |
| 2021-12-31 | $-34.40M | (m) | (m) | $22.48M | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-52.24M | (m) | (m) | $45.21M | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |